Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats skin and skin structure infections caused by Escherichia coli, Klebsiella…. Sold as Cipro, Cipro In Dextrose 5% In Plastic Container, Cipro In Sodium Chloride 0.9% In Plastic Container, Otiprio. Every FDA application for this active ingredient: 5 branded and 20 generic.
As of Nov 15, 2026, FDA lists 25 applications for Ciprofloxacin (sold as Cipro, Cipro In Dextrose 5% In Plastic Container, Cipro In Sodium Chloride 0.9% In Plastic Container and others), first approved Dec 26, 1990, with 32 new uses approved and 0 published complete response letters.
First approved: Dec 26, 1990
Applications: 25
New uses approved: 32
Complete response letters: 0
Medicare spending, 2025: $26.9M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Ciprofloxacin HCl
Part D
$25.4M
-22%
3,435,948
Ciloxan
Part D
$1.1M
-30%
2,587
Cipro
Part D
$380K
-10%
1,880
Ciprofloxacin
Part D
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
CIPROFLOXACIN 0.2% OTIC SOLN: $6.50 per unitGeneric · -12% in a year
CIPROFLOXACIN 0.3% EYE DROP: $1.48 per MLGeneric · -11% in a year
CIPROFLOXACIN HCL 250 MG TAB: $0.080 per unitGeneric · -12% in a year
CIPROFLOXACIN HCL 500 MG TAB: $0.121 per unitGeneric · -11% in a year
CIPROFLOXACIN HCL 750 MG TAB: $0.245 per unitGeneric · -5% in a year
CIPRO 10% SUSPENSION: $1.45 per MLBrand · 0% in a year
CIPRO 5% SUSPENSION: $1.25 per MLBrand · 0% in a year
Ciproxan-I.V.A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for… · Bayer Yakuhin, Ltd. · Sep 24, 2015
Clinical Trials
56 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Bayer Hlthcare
Hikma
Fresenius Kabi USA
Baxter Hlthcare